Abstract

Epidermodysplasia verruciformis (EV) is a rarely seen, genetically transmitted dermatosis characterized by the tendency to human
papillomavirus infections (HPV). Although its etiopathogenesis is not exactly known, dysfunction in cell-mediated immunity is thought to be
a very important factor in the development of the disease. Verruca plana, which starts in childhood, and reddish-brown papules and
plaques mimicking pityriasis versicolor are seen in EV cases. There are no specific races or geographical differences in the incidence of the
disease. On histopathological examination, hiperkeratosis, acanthosis, and intense vacuolization similar to those in classic verruca vulgaris
can be seen. Especially in the sun-exposed areas, malignancies may develop. Therefore, early diagnosis and treatment of the disease is
significant for the prevention of premalignant and malignant lesions. Some medications such as interferon, retinoic acid, topical imiquimod
can be used in the treatment. Here, we present a 14-year-old epidermodysplasia verruciformis case having partially positive response to
acitretin treatment
Epidermodysplasia Verruciformis (EV); Human Papillomavirus (HPV); Acitretin.